SEC Comment Letter for ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA) — Jan 15, 2020
ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: Jan. 15, 2020 · CIK: 0001681682 · Accession: 0000000000-20-000371
AI Filing Summary & Sentiment
File numbers found in text: 333-235883
Letter
January 15, 2020 Francois Michelon Chief Executive Officer ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105 Re:ENDRA Life Sciences Inc. Registration Statement on Form S-3 Filed January 10, 2020 File No. 333-235883 Dear Mr. Michelon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark R. Busch, Esq.
Show Raw Text
January 15, 2020
Francois Michelon
Chief Executive Officer
ENDRA Life Sciences Inc.
3600 Green Court, Suite 350
Ann Arbor, MI 48105
Re:ENDRA Life Sciences Inc.
Registration Statement on Form S-3
Filed January 10, 2020
File No. 333-235883
Dear Mr. Michelon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mark R. Busch, Esq.